Recombinant viral-based malaria vaccines

Plasmodium P. falciparum P. yoeliiThe present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different infections, such a...

Full description

Saved in:
Bibliographic Details
Main Authors Pau, Maria G, Holterman, Lennart, Kaspers, Jorn, Stegmann, Antonius J. H
Format Patent
LanguageEnglish
Published 11.01.2011
Online AccessGet full text

Cover

Loading…
More Information
Summary:Plasmodium P. falciparum P. yoeliiThe present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different infections, such as infections by or . Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.